home / stock / ormp / ormp news


ORMP News and Press, Oramed Pharmaceuticals Inc. From 09/09/21

Stock Information

Company Name: Oramed Pharmaceuticals Inc.
Stock Symbol: ORMP
Market: NASDAQ
Website: oramed.com

Menu

ORMP ORMP Quote ORMP Short ORMP News ORMP Articles ORMP Message Board
Get ORMP Alerts

News, Short Squeeze, Breakout and More Instantly...

ORMP - Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire NEW YORK , Sept. 9, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused...

ORMP - GSAT, GDP and ASMB among mid-day movers

Gainers: Sphere 3D (NASDAQ:ANY) +50%. Data Storage (NASDAQ:DTST) +28%. Cloopen Group (NYSE:RAAS) +26%. Aurora Mobile (NASDAQ:JG) +21%. Liquid Media (NASDAQ:YVR) +21%. Globalstar (NYSE:GSAT) +20%. TSR (NASDAQ:TSRI) +19%. The L.S. Starrett (NYSE:SCX) +18%. Tiziana Life Sciences (NASDAQ:TLSA) +1...

ORMP - Wall Street Breakfast: Ida Remnants Batter Northeast (Podcast)

Read the full story here: For further details see: Wall Street Breakfast: Ida Remnants Batter Northeast (Podcast)

ORMP - Wall Street Breakfast: Wallet Extinction

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Wallet extinctionIn a major expansion of its app-based services, Apple (AAPL) has lined up the first U.S. states to allow drivers to store their licenses w...

ORMP - Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials - ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol currently underway - ORA-D-013-1, the larger and first of the 2-part trial to commence, nears 65% enrollment PR ...

ORMP - Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism PR Newswire NEW YORK , Aug. 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) ( www.oramed.com ), a clinical-stage p...

ORMP - FCEL, MVST and ASTR among pre market gainers

Lightning eMotors ZEV +44% on signing largest contract ever in the electric shuttle bus market with Forest River Fulcrum Therapeutics FULC +53% on early-stage results for sickle cell disease therapy IMV IMV +39% on promising maveropepimut-S data in ovarian cancer...

ORMP - Shares of Oramed Pharmaceuticals Inc. (ORMP) Rise to a New 52-Week High

Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) traded today at $20.37, eclipsing its 52-week high. This new high was reached on below average trading volume as 251,000 shares traded hands, while the average 30-day volume is approximately 784,000 shares. Oramed Pharmaceuticals Inc is...

ORMP - Oramed to Present at Canaccord Genuity's 41st Annual Growth Conference

Oramed to Present at Canaccord Genuity's 41st Annual Growth Conference PR Newswire NEW YORK , Aug. 9, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the devel...

ORMP - HIMX, ORMP AND BITF among pre market gainers

Sphere 3D Corp (NASDAQ:ANY) +43% agreement to acquire exclusive rights for assignment of cryptocurrency mining assets Kaixin Auto (NASDAQ:KXIN) +23% on foraying into new energy vehicle business Switch (NYSE:SWCH) +19% on Q2 earnings Westport Fuel (NASDAQ:WPRT) +1...

Previous 10 Next 10